Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 944-948

  El Annaz, Hicham ^a   Recordon Pinson, Patricia ^b   Tagajdid, Rida ^a   Doblali, Toufik ^a   Belefquih, Bouchra ^a   Oumakhir, Siham ^a   Sedrati, Omar ^a   Mrani, Saad ^a   Fleury, Hervé ^b  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b University Victor Segalen   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MALE; MOROCCO; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SAMPLE; VIRUS ISOLATION; VIRUS MUTATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOROCCO; MUTATION; TREATMENT FAILURE; YOUNG ADULT;

EID: 84864231165     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0278     Document Type: Article

References (30)

1. Cortez KJ and Maldarelli F: Clinical management of HIV drug resistance viruses 2011. Viruses 2011;3,347-378.
2. Vella S and Palmisano L: The global status of resistance to antiretroviral drugs. Clin Infect Dis 2005;41(Suppl 4):S239-S246.
3. Kozal MJ, Hullsiek KH, Macarthur RD, et al.: The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007;8:357-370.
4. Loubiere S, el Filal KM, Sodqi M, et al.: When to initiate highly active antiretroviral therapy in low-resource settings: The Moroccan experience. Antivir Ther 2008;13(2):241-251.
5. EL Annaz H, Recordon-Pinson P, Baba N et al.: Presence of drug resistance mutations among drug-naive patients in Morocco. AIDS Res Hum Retroviruses 2011;27(8):917-920.
6. ANRS-AC 11: Resistance Group. Genotype interpretation: Nucleoside and nucleotide reverse transcriptase inhibitors. July 2010-Version no. 19.
7. El Aouad R, Diez M, and Cherkaoui I: Impact of immigration on HIV and tuberculosis epidemiology in the Euro- Mediterranean area. Euro Surveill 2009;14(15):pii = 19173.
8. Marconi Vincent C., Sunpath Henry, Zhigang Lu, et al.: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46(10):1589-1597.
9. Weidle PJ, Malamba S, Mwebaze R, et al.: Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002;360:34-40.
10. Cavalcanti AM, Lacerda HR, Brito AM, et al.: Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil. Mem Inst Oswaldo Cruz 2007;102:785-792.
11. Costagliola D, Descamps D, Assoumou L, et al.: Prevalence of HIV-1 drug resistance in treated patients: A French nationwide study. J Acquir Immune Defic Syndr 2007;46(1):12-18.
12. Pillay D, Green H, Matthias R, et al.: Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005;192(6):967-973.
13. Harrigan PR, Hogg RS, Dong WW, et al.: Predictors of HIV drug-resistance mutations in a large antiretroviral naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191(3):339-347.
14. Tamalet C, Fantini J, Tourres C, et al.: Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003;17:2383-2388.
15. Richman DD, Morton SC, Wrin T, et al.: The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-1401.
16. Gallego O, Ruiz L, Vallejo A, et al.: Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 2002;40:3865-3866.
17. Rhee SY, Liu T, Ravela J, et al.: Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004;48:3122-3126.
18. Zazzi M, Corsi P, Gonnelli A, et al.: Evolution of the prevalence of HIV drug resistance patterns over 9 years of HAART and its relation with changes in the failing treatment regimens: An analysis of a large Italian database. XV International HIV Drug Resistance Workshop, Sitges, Spain. Antivir Ther 2006:S137.
19. Volberding PA and Deeks SG: Antiretroviral therapy and management of HIV infection. Lancet 2010;376:49-62.
20. Khachani I, Harmouche H, Ammouri W, et al.: Impact of a psychoeducative intervention on adherence to HAART among low-literacy patients in a resource-limited setting: The case of an Arab Country: Morocco. J Int Assoc Physicians AIDS Care 2011 [Epub ahead of print]; DOI:10.1177/ 1545109710397891.
21. Philips AN, Dunn D, Sabin C, et al.: Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494.
22. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
23. Sukasem C, Churdboonchart V, Chasombat S, et al.: Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: Under the initiative of access to the NNRTI-based regimen in Thailand. J Chemother 2007; 19(5):528-535.
24. Toledo PVM, Siqueira De Carvalho D, Romagnoli L, et al.: HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná , Brazil. Braz J Infect Dis 2010;14(4):360-371.
25. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al.: The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23(9):1127-1134.
26. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, et al.: Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio De Janeiro, Brazil: Assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2005;100:73.
27. Gupta R, Hill A, Sawyer AW, et al.: Emergence of drug resistance in HIV type 1-infected patients after receipt of firstline highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis 2008;47:712-722.
28. Tozzi V, Zaccarelli M, Bonfigli S et al.: Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: Prevalence, risk factors and virological outcome. Antiviral Ther 2006;11:553-560.
29. Westin MR, Biscione FM, Fonseca M, et al.: Resistance-associated mutation prevalence according to subtypes B and Non-B of HIV Type 1 in antiretroviral-experienced patients in Minas Gerais, Brazil. AIDS Res Hum Retroviruses 2011;27(9):981-987.
30. Silva MM, Telles FQ, da Cunha CA, et al.: HIV subtype, epidemiological and mutational correlations in patients from Paraná , Brazil Braz J Infect Dis 2010;14(5):495-501.